Reimbursement: The New Biopharma Investment Hurdle
With a growing number of expensive therapeutics entering the market and rising pressures to contain costs, gauging reimbursement is now a crucial element deal makers must evaluate.
You may also be interested in...
Lured by the success of Abbott in rheumatology, Novartis in oncology, and Genzyme in orphan/genetic diseases, pharmaceutical manufacturers have turned their collective sights on specialist-driven markets. But payor pressure is ballooning and as examples in these hotly competitive areas demonstrate, to truly succeed in specialist markets, companies cannot rely on a ‘follower’ strategy. Instead, careful selection of indications where true innovation is possible and fostering meaningful interaction with physicians and patient communities will allow pharmaceutical companies to grow specialty franchises alongside traditional strengths.
After a long period when only the bravest, well-funded biotechs attempted to build a commercial organization, more companies than ever are taking the go-it-alone plunge. Campbell Alliance thinks we may look back on the commercializing classes of 2011–2012 for key lessons on what drives success, which companies created value and how, and when market challenges prove too much for a new organization.
The biotech financing drought, combined with increasing externalization of pharma R&D, should be creating an ideal climate for successful dealmaking. Yet executing partnerships between biopharma sellers and buyers remains incredibly challenging. Locust Walk Partners surveyed senior business development executives to find the keys to executing mutually satisfying deals.